Stoke Therapeutics (STOK) Receives a Buy from BTIG

In a report issued on March 10, Thomas Shrader from BTIG maintained a Buy rating on Stoke Therapeutics (STOKResearch Report), with a price target of $83.00. The company’s shares closed last Friday at $26.10.

According to, Shrader is a 1-star analyst with an average return of -0.3% and a 31.9% success rate. Shrader covers the Healthcare sector, focusing on stocks such as Minerva Neurosciences, Aldeyra Therapeutics, and Sigilon Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Stoke Therapeutics with a $61.60 average price target, representing a 162.9% upside. In a report issued on March 16, Bank of America Securities also maintained a Buy rating on the stock with a $40.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Stoke Therapeutics’ market cap is currently $975.1M and has a P/E ratio of -11.18.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stoke Therapeutics, Inc. engages in the research and development of treatments for genetic diseases. It is a biotechnology firm that focuses to increase gene expression to treat severe genetic diseases, including genetic conditions affecting the central nervous system, eye, ear, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.

Read More on STOK:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More